Skip to main content

Table 2 Results of an MTC of success rate for ivermectin 1 % cream QD versus other available topical treatments and vehicle at 12 weeks

From: The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis

Comparator treatment 12 weeks
12 studies
RR (95 % Crl) (vs. ivermectin 1 % cream QD)
 Azelaic acid 15 % gel QD 1.33 (0.99 to 2.20)
 Azelaic acid 15 % gel BID 1.25 (1.14 to 1.37)
 Metronidazole 0.75 % cream BID 1.17 (1.08 to 1.29)
 Metronidazole 1 % gel QD 1.18 (0.98 to 1.56)
 Silica encapsulated benzoyl peroxide 1 % gel QD 1.09 (0.86 to 1.78)
 Silica encapsulated benzoyl peroxide 5 % gel QD 0.94 (0.81 to 1.29)
 Vehicle 1.56 (1.46 to 1.65)
NNT (95 % Crl) (vs. vehicle)
 Azelaic acid 15 % gel QD 7 (−120 to 120)
 Azelaic acid 15 % gel BID 9 (6 to 14)
 Metronidazole 0.75 % cream BID 6 (4 to 13)
 Metronidazole 1 % gel QD 6 (3 to 41)
 Silica encapsulated benzoyl peroxide 1 % gel QD 4 (−31 to 44)
 Silica encapsulated benzoyl peroxide 5 % gel QD 3 (2 to 9)
 Ivermectin 1 % cream QD 3 (3 to 4)
  1. Risk ratios evaluate the probability of success (relieving rosacea) when using ivermectin 1 % cream QD, compared to other comparator treatments. A risk ratio >1 demonstrates a greater likelihood of success using ivermectin 1 % cream QD, a RR Crl that does not cross 1 demonstrates a significant difference between ivermectin and the comparator (positive values indicate superiority, negative values indicate inferiority) (indicated in italic). Lower estimates of NNT indicate a greater likelihood of patients achieving success with ivermectin 1 % cream QD, as fewer patients need to be treated to achieve one success than with the comparator treatment. A positive Crl indicates a significantly greater likelihood of patients achieving success when using ivermectin 1 % cream QD than when using the comparator (indicated in italic). Studies contributing to 12 week analysis: Galderma (2006, 2014), Thiboutot et al. (2008), Wolf et al. (2006), NCT00617903 (2013), Draelos et al. (2013, 2015), Stein et al. (2014), Thiboutot et al. (2003), Leyden (2014), Gold et al. (2014a); 3, 9, and 15 weeks results available in Additional file 1: Table 7. MTC results are derived from a fixed effects model. At 15 weeks, ivermectin vs. vehicle data were limited, and so metronidazole 0.75 % BID was used as the bridging comparator for NNT
  2. BID twice daily, Crl credible interval, MTC mixed treatment comparison, NNT number needed-to-treat, QD once daily, RR risk ratio